Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Share-based Compensation: 2022-2025

Historic Share-based Compensation for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $67,132.

  • bioAffinity Technologies' Share-based Compensation fell 63.85% to $67,132 in Q3 2025 from the same period last year, while for Sep 2025 it was $839,442, marking a year-over-year decrease of 15.31%. This contributed to the annual value of $989,681 for FY2024, which is 32.16% up from last year.
  • Per bioAffinity Technologies' latest filing, its Share-based Compensation stood at $67,132 for Q3 2025, which was down 68.28% from $211,607 recorded in Q2 2025.
  • bioAffinity Technologies' Share-based Compensation's 5-year high stood at $326,616 during Q1 2025, with a 5-year trough of $26,685 in Q2 2022.
  • Moreover, its 3-year median value for Share-based Compensation was $211,607 (2025), whereas its average is $203,978.
  • Its Share-based Compensation has fluctuated over the past 5 years, first spiked by 538.01% in 2023, then plummeted by 63.85% in 2025.
  • Over the past 4 years, bioAffinity Technologies' Share-based Compensation (Quarterly) stood at $36,847 in 2022, then surged by 536.44% to $234,510 in 2023, then declined by 0.18% to $234,087 in 2024, then tumbled by 63.85% to $67,132 in 2025.
  • Its Share-based Compensation stands at $67,132 for Q3 2025, versus $211,607 for Q2 2025 and $326,616 for Q1 2025.